Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741871 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma, sponsored by S*BIO.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00741871 is a Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma that has completed, run by S*BIO. The registered enrollment target is 35 participants, below the 89-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00741871, a Phase 1 study of B-cell Lymphoma and Hodgkin's Lymphoma, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
Conditions Studied
Interventions
- DRUG SB1518
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741871
The ClinicalTrials.gov registry entry for NCT00741871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (61% lower). The listed sponsor is S*BIO, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SB1518 is the first listed.
NCT00741871 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00741871 about?
NCT00741871 is a clinical study titled "A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies". This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
What is the current status of trial NCT00741871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-07. Estimated completion is 2011-10.
What conditions does trial NCT00741871 study?
This clinical trial studies the following conditions: B-cell Lymphoma, Hodgkin's Lymphoma, Lymphoma, Malignant.
What interventions are being tested in trial NCT00741871?
The interventions under investigation include: SB1518 (DRUG).
Who is sponsoring clinical trial NCT00741871?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00741871 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.